This week we'll discuss a randomized controlled-ish trial, the RIM study.  It pits rituximab against placebo as well as... rituximab? We'll talk about how their design convincingly demonstrated that ritixan does not have a benefit over placebo for 8 weeks, but may or may not work after that. Find the trial itself here. 

This week we'll discuss a recent trial on mepolizumab - and IL-5 inhibitor - for eosinophilic granulomatosis with polyangiitits.  Find the paper here and be sure to follow us on twitter @JBRheum! 

Today we'll be discussing the ALMS trial, which pitted cellcept against cyclophosphamide.  It's a good trial that has had profound influences on our practice and well worth a read. Access the paper itself here.

Welcome back!  Before we talk about cellcept for lupus nephritis, I decided we should flash back to 1996 and discuss one of the early trials that brought us cyclophosphamide.  It's a quick discussion that will help set us up nicely for ALMS this Sunday.  Remember to follow us on Twitter @JBRheum for updates! Access the paper here.

This week we'll be discussing a trial addressing a controversial topic - starting allopurinol during an acute attack of gout.  It's a short podcast on a short paper, but one that could have a big impact on your practice. Be sure to follow us on Twitter @EBRheum! Access the paper itself here.

Today we discuss a recent letter in JAMA-Internal medicine.  Find the original paper here and be sure to subscribe to the podcast!